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CHAPTER 1 INTRODUCTION
1.1 Diabetes mellitus and Insulin resistance
Diabetes mellitus, or simply diabetes, is a metabolic disorder that is
marked by hyperglycemia, high blood glucose. In 2014, 29.1 million individuals in
the United States, which is about 9.3% of the population, have diabetes [1].
Among all cases of diabetes, about 90% to 95% are Type 2 Diabetes (T2D), the
diabetes form generally results from defects in insulin action [1]. Furthermore,
other related complications of diabetes will afflict patients with their cardinal,
ocular,

renal,

and

nervous

system

dysfunction,

mainly

resulting

from

hyperglycemia [2].

1.1.1 History of Diabetes
Unfortunately, though recognition of diabetes has gradually been
increasing over 200 years and some progresses have been achieved, there is
still no cure for diabetes [3]. One of the possible reasons is that the signaling
events related to insulin are quite complicated in both Langerhans islet cells and
insulin responsive cells that hundreds of signaling events directly or indirectly
involved in the insulin pathway contribute to regulation of insulin level and
regulated metabolic function. The relationship of these signaling events with
insulin signaling is revealed gradually in several decades, which has been
viewed as a remarkable milestone in the history of insulin research. Ironically,
discovering something unknown in science is always another step into a new
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field, which leads to arising of more mysteries. As a consequence, another
aspect for complicity of diabetes lies in the discovering of the mechanism of T2D.
During the early stage in the history of diabetes research, diabetes was
considered as a disease due to deficiency of insulin produced by islet cells of
Langerhans, which, we know nowadays, is shown in most Type 1 Diabetes (T1D)
patients and some Type 2 Diabetes (T2D) patients. Distinction between T1D and
T2D has first been made in 1936, based on their different pathogenesis [3].
Type 1 Diabetes usually onsets at very early age of patients, thus it is also
named as “juvenile diabetes”, informally. The cause of T1D is hypothesized to be
the destruction effect of autoimmune selectively to insulin producing cells, which
will lead to further metabolic changes linked to hyperglycemia. Genetic disorder
and environment factors may explain most case in T1D [3, 4].
Even though the primary cause of T2D is unclear, continuous research on
the metabolic syndrome over several decades has improved awareness of the
complex pathogenesis from which the development and the outcome of T2D
results. Originally, T2D is thought to develop most often in middle-aged and older
population, but in recent years, the upward trend in occurrence of T2D has been
shown in young population. Also, the relation between occurrence of T2D and
overweight has been affirmed [3, 5]. However, the complexity of T2D attributes
most to multi-stage involved in the course of disease development, as well as the
interaction between various organs and tissues. Despite the primary factor of the
disease is unknown, insulin resistance is consented to be the initiator in early
stage which is followed by pancreatic beta cell decompensation [6]. In year 2035,
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T2D is expected to agonize more than 530 million people worldwide [7], hence to
gain a more thorough understanding of T2D mechanism is considered to be a
leading step to conquer the abominable disease.

1.1.2 Insulin resistance
As a major player in T2D development, insulin resistance has been
recognized for almost a century and systematically research has been conducted
since 1970s [8]. In general, insulin resistance connotes metabolic abnormal state
that glucose uptake tissues in an individual are unable to act normally as in
healthy population under given quantity of insulin. Individuals with insulin
resistance sustain compensatory hyperinsulinemia over hyperglycemia and once
the compensation ability of beta cells is overwhelmed by insulin demand,
diabetes follows. Also, obesity is considered as a major factor associated with
insulin resistance [9]. Thus, researches on the relationship of obesity, insulin
resistance and T2D, namely, the “adipo-insulin axis”, have been a hotspot
recently [10].
The association of T2D with insulin resistance has been studied for
decades, and several lines of evidence have been found [6, 11]:
First, prospective studies illustrate that onset of T2D develops average 1
to 2 decades after the occurrence of insulin resistance. Second, basically insulin
resistance is an accordant feature of every T2D patient. Third, insulin resistance
works as the best predictor for T2D in the offspring whose parents were T2D
patients. Finally, increasing insulin sensitivity is a way to lower the incidence of
T2D.
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1.1.3 Signaling associated with Insulin Sensitivity
Though insulin sensitivity fluctuates within healthy individuals, and insulin
sensitivity occurs normally during puberty, pregnancy, and gaining age [12], the
most outstanding factor in diabetes researches is unhealthy lifestyle, and its
related disease, obesity. Obesity will further increase the risk for developing T2D
and other metabolic syndromes. One of the most distinct characters in obesity
state is alteration of releasing Non-esterified fatty acids (NEFAs), hormones and
pro-inflammatory cytokines from adipose tissue [12]. These adipose-derived
factors will affect other insulin signaling related tissues, including skeletal muscle,
liver, and other tissues. The influence will be expressed in functional changes
which associate with multiple signaling pathways, which eventually results in the
onset of insulin resistance. Two of these pathways, PI3k-AKT and MAPK, are
directly activated by insulin receptor-mediated tyrosine phosphorylation of insulin
receptor substrates, and other factors involve in inflammatory process, such as
TNF- α, IL-6, MCP-1, and IL-8 [13].
The PI3k-AKT pathway, as the most well-known and vital player in insulin
signaling, will be provided detailed introduction in the subsequent sections.
MAPK pathway activation by insulin signaling functions in gene expression, cell
growth and mitogenesis, related to the PI3K-AKT pathway [13]. It has been
reported that in the skeletal muscle, T2D and obesity individuals with insulin
resistance show abnormally low activity in the PI3K pathway, while relatively
normal in the MAPK pathway, compare to healthy individuals [14]. Nevertheless,
since MAPK can phosphorylate specific serine sites of IRS1, abnormal activity of
MAPK will aggravate insulin resistance when IRS1 has already been impaired
4
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[15]. Additionally, growing evidence has directed to a causative relationship
between inflammation and insulin resistance. In obese patients, plasma level of
C-reactive protein and inflammatory cytokines shows an incremental change,
suggesting that a chronic low-grade inflammation occurs [13]. Other study
suggests the inflammation mediators induce insulin resistance through activating
JNK and the IκB kinase-β (IKK-β) pathways [12].

1.2 PP1c and Phosphorylation, and Insulin resistance
Protein phosphorylation is one of the most essential post-transcriptional
regulations and being viewed as a principle currency of signaling pathways.
Many important cellular processes rely on protein phosphorylation, including
insulin signaling. Dysregulation of protein phosphorylation leads to turbulence of
cell signaling, and function disorder, such as insulin resistance and T2D. For
instance, phosphorylation on serine/threonine sites of IRS1 is considered as a
potential source of insulin resistance [16, 17]. As a phosphatase, Protein
Phosphatase 1 (PP1) aims to dephosphorylate the protein substrates that have
been phosphorylated. Research on PP1 might be a viable way to understand and
eventually conquer T2D.

1.2.1 PI3k-AKT-mTOR Pathway
Phosphoinositide 3-kinase (PI3K) pathway has originally been viewed as a
component of insulin signaling. However, highly conserved PI3k pathway has
also been proved to involve in multiple cellular processes except for insulin
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signaling, i.e. cancer. Through later studies, a model of PI3k-AKT-mTOR signal
chain has been gradually polishing and finally established [18] (See Fig 2).
As the major trigger of PI3K pathway, insulin molecules relay the signal through
insulin receptor to insulin receptor substrates (IRS). As an adaptor protein,
activated IRS1 will recruit p85 subunit of class 1A PI3K, which initiates the
activation

of

PI3K.

Activated

PI3K

catalyzes

phosphorylation

of

phosphatidylinositol 4, 5-bisphosphate (PIP2) to produce phosphatidylinositol 3,
4, 5-trisphosphate (PIP3). Enhanced PIP3 level allows binding and activating of
PDK1, and the later will phosphorylate and activate PKB/Akt that is also recruit to
plasma membrane by PIP3 [15, 18]. Activated PKB/Akt triggers formation of
mTOR/RAPTOR complex which participates in protein synthesis. In addition,
PKB/Akt will be a participant in glycogen synthesis through activating GSK3 and
in glucose uptake by conducting GLUT4 vesicle translocation mediated by
AS160 [18, 19].
As mentioned above, PI3K pathway associates closely with insulin
resistance. However, in skeletal muscle, a well-known factor in the PI3K pathway
that involves in insulin resistance is serine/ threonine phosphorylation of IRS1.
While tyrosine phosphorylation of IRS1 enables binding of downstream proteins
in PI3K pathway [20], function of serine/ threonine phosphorylation of IRS is sitespecific: either increase or diminish insulin signaling. The dual role of serine/
threonine phosphorylation engenders regulation of different mechanisms, such
as tyrosine phosphorylation state of IRS, binding to insulin receptor, subcellular
dynamics, and degradation [21]. Though positively regulation of insulin signaling
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has been reported, most of serine/ threonine phosphorylation of IRS negatively
control insulin signaling [20]. However, in insulin resistance state, usually seen in
obesity and T2D patients, serine/ threonine phosphorylation of IRS molecules is
abnormally regulated by multiple kinases [22], leading to dysregulation of insulin
signaling. Increased in serine/ threonine phosphorylation of IRS is seen as a
noticeable tag of insulin resistance in both animal and human studies [15]. Hence,
to find a way to dephosphorylate abnormally regulated serine/ threonine sites of
IRS might be an accessible avenue to T2D treatment.

1.2.2 Phosphatases: Function, Category and Families
Phosphorylation is one of the most essential and wide-spread posttranslational modifications in cells: it rapidly and efficiently alters activity, protein
binding and structure of its substrates. Generally, there are two players compete
in the area of phosphorylation; protein kinases phosphorylate substrates, while
protein phosphatases dephosphorylate substrates. However, not all the amino
acids can be phosphorylated; serine, threonine and tyrosine account for most
cases in which phosphorylation occurs in mammalian cells.
The classical categorization [23, 24] of phosphatases subdivided them into
three basic families: PPP (phosphoprotein phosphatase), PPM (metallodependent protein phosphatase), and PTP (protein tyrosine phosphatases)
families. The emerging researches [25, 26] replenish more subdivided families on
the basis of different structure domains and evolutionary origins, without
consensus. Essentially, the PTP members dephosphorylate tyrosine residues
only, while the PPP and PPM family comprise of serine / threonine phosphatases;
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the PPM family members are Mg2+-dependent phosphatases, and the PPP
family is a traditional serine / threonine phosphatase family with several wellknown members, such as PP1, PP2A, PP2B (calcineurin), PP4, PP5, PP6 and
PP7 [27] [28]. Other reviews [25] also include PPEF1 and PPEF2 in this family.
These members in PPP family share highly conserved sequence and catalytic
motif of their catalytic subunits [26].
Intriguingly, in 518 kinases encoded by human genome, only 90 of them
are tyrosine kinases; that is similar with the total number of tyrosine
phosphatases [25]. The remaining 428 out of 518 kinases are serine/ threonine
kinases [25], which is at least 4 times more than total number of serine/ threonine
phosphatases. Over years, much of interest of science researchers focuses on a
question raised with the huge divergence between number of serine/ threonine
kinases and phosphatases: how do such a limited number of phosphatase
offsets phosphorylation by kinases in an organized manner?

1.2.3 Introduction of Protein Phosphatase 1 Catalytic Subunit
As the first serine/ threonine phosphatase has been discovered, studies
on Protein Phosphatase 1 (PP1) have never stopped over the past four decades
[29]. Many studies have been done on isoforms, structure and functions of PP1.
PP1 is not a monomeric enzyme itself; it contains 2 subunits, the Catalytic
subunits (PP1c) and the Regulatory subunits (PP1r). Generally speaking, 3
isoforms exist for PP1c: PPP1CA, PPP1CB and PPP1CC. Among each isoforms,
highly sequence conservation is observed (Fig 3) —PPP1CA isoform shares
86.7% and 89.8% identity with PPP1CB and PPP1CC, respectively. Alternatively
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splicing isoforms exist under each isoforms [28]. Although the 3 isoforms of PP1c
encode by different genes, and they show diverse tissue and subcellular
distribution, it is safe to regard these isoforms altogether in our research since
they share remarkably similar features when they enact their functions in cells
[28].
For last decades, it has always been an arduous mission to unravel
function motifs of PP1c. In general, two categories of motifs (Fig 4b), binding
motifs and catalytic motifs, characterize most essential functions of PP1c. PP1c
catalytic core locates in the center of its sequence (residues 41–269 of the α
isoform) [30]. Residues associate with catalytic reaction distribute on catalytic
core. PP1c engenders catalytic reaction to its substrate simply relies on two
divalent metals, usually Iron (Fe2+) and Zinc (Zn2+) in mammalian cells, and
Manganese (Mn2+) in bacteria [31]. Metal binding residues on PP1c concentrate
in several sites: Asp64, His66, Asp92, Asn124, His173, and His248 [32].
However, to achieve specificity, PP1c also needs to bind other components of
PP1 holoenzyme, namely PP1 regulatory subunits (See below). Studies [28] on
structure of PP1 holoenzyme unveil that multiple sites contact with regulatory
subunits on PP1c. The essential interactions between PP1c and PP1r comprise
of 2 groups, polar interaction and hydrophobic interaction, the sites of which
disperse in whole sequence. In general, polar interaction occurs on site Asp242,
Leu289, Cys291, and Glu287; while hydrophobic interaction appears in site
Ile169, Leu243, Asp242, Leu289, Cys291 Phe257, Phe293, and Met290 [33]. On
the other hand, researches on direct interaction partners of PP1c manifest the
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widespread consensus amino acid sequence, R/K-X(0,1)-V/I-{P}-F/W, where
X(0,1) represents none or any amino acid, and {P} stands for any amino acid
except for Proline, overlaps through most binding partners [33, 34]. Other
docking motif (F-x-x-R/K-x-R/K) has been reported elsewhere [35]. The docking
motifs of PP1c could become a predictive clue to discover and validate PP1interaction partners (PIP).
3D structure of PP1c (Fig 4a) has been illustrated by X-ray crystallography
for almost 20 years [36]. Three “grooves”, hydrophobic groove, acidic groove,
and C-terminal groove, can be identified from the surface of PP1c (Fig 5), on
which PP1c binding sites locate [32, 33].
A protein’s role is defined in its interactions with other proteins. PP1 and
PP2A are the essential members of PPP family that account for about 90% of
phosphatase activity in eukaryotes. Compared with PP2A (contains only 70
holoenzymes), PP1 is reported to form more than 650 holoenzymes.
Consequently PP1 is considered to conduct majority of phosphatase activity [31].
Although the number of catalytic subunit of the protein phosphatase is limited
and highly evolutionary conserved, a spectrum of interaction partners interacts
with each phosphatase, providing specificity (Fig 5). Thus, PP1 regulates its
substrates not by increasing gene duplication, but through its outstanding ability
to establish interactome. Currently, there are nearly 500 proteins have been
predicted

to

be

the

PIPs

so

far.

Principally,

PIPs

either

regulate

dephosphorylation activity of PP1c, target PP1c to its substrate, or serve as
PP1c substrates. In particular, 6 aspects of interaction (Fig 6) can be achieved
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through regulation of PIP. Though such a huge number of PIPs has been
discovered, there is no relatively large scale PIPs profiling of PP1c (i.e., PP1c
interactome) in human skeletal muscle, which is the major aim in this project.

1.3 Hyperinsulinemic-euglycemic Clamps and Skeletal Muscle
1.3.1 Hyperinsulinemic-euglycemic Clamps
As mentioned above, insulin resistance is a predictable signature of T2D
and other metabolic diseases. Clinically, to quantify insulin sensitivity, several
methods have been used, such as Oral Glucose Tolerance Test (OGTT), Insulin
Tolerance Test (ITT), and Glucose Clamps [37]. However, to investigate insulin
sensitivity of insulin responsive tissues, e.g. skeletal muscle, the “Gold Standard”
is the Hyperinsulinemic-euglycemic Clamp [38], developed by Dr. DeFronzo et al.
in 1979 [39].

1.3.2 Tissues response to Insulin
Development of T2D is a combination of actions from multiple tissues. In
T2D, insulin resistance in insulin responsive tissues, including Hepatic IR,
Adipose Tissue IR, and Skeletal Muscle IR, plays an important role [40]. Liver
and adipose tissue are primary targets of insulin. They will react to insulin signal
and hence adjust their function in metabolism, such as gluconeogenesis, de novo
lipogenesis, and lipolysis. In T2D, several classical effects connect to insulin
resistance of liver and adipose tissue, e.g. increased free fatty acid turnover [40]
and lipotoxicity [41]. Moreover, liver and adipose tissue also show turbulence of
signaling transduction, indirectly affecting other tissues, such as skeletal muscle.
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Although brain will not change glucose uptake per se to insulin level, it will
process and response to the signal and regulate insulin responsive tissues by
signaling transmission [42]. In addition, at early stage of T2D, β-cells are trying
to compensate blood glucose increase by producing more insulin. However,
when ability to produce insulin is overwhelmed by hyperglycemia, β-cell
dysfunction occurs [43].

1.3.3 Studying skeletal muscle as a promising approach in T2D
research
As largest energy storage tissues and insulin secretion tissue in human
body respectively, liver [40], adipose tissue [41] and Langerhans islet [44] have
been well studied. However, it is disappointing to see that studies focusing on
another equal important tissue connect with insulin-energy-regulation in human,
skeletal muscle have been underestimated. On the contrary to this situation,
during T2D, it has long been seen as a fact that the defect in glucose disposal
exits mostly in skeletal muscle cells, while liver, adipose tissue, and brain
glucose uptake level shows barely significant change between T2D patients and
controls (Fig 7). Furthermore, skeletal muscle, as the signal terminal of insulin
signaling and other signals associating with insulin resistance, expresses
assorted distinct features in aberrant protein-protein interactions during insulin
resistance and T2D [45]. However, interaction partners of PP1c in skeletal
muscle remain unexplored. Therefore, this project aims to uncover protein
interaction partners in skeletal muscle in human.
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1.4 Mass Spectrometry
interactions

in

discovery

of

protein-protein

Multiple methods can be used in studying in PP1c interaction partners.
These methods [46] include, but not limited to protein phosphatase assay, yeast
two hybrid, PP1 overlay assay, GST pull-downs, co-immunoprecipitation,
microcystin-sepharose column, florescence technique, such as FRET [47] and
FRAP [48], are widely utilized in identifying PIPs. However, these methods either
show low-throughput, low accuracy, or extremely high complicity. As a
consequence, proteomic approach combining with mass spectrometry provides
an effective solution.
Cells can be simplified as a factory, in which a plenty of workers, such as
proteins, DNAs, and RNAs, works on numerous assembly lines (pathways), and
finally elicits different products (biological processes). To characterize outcomes
of cellular signaling, understanding single component or isolated interaction is
much less than enough. Above mentioned traditional methods display limitation
in the absence of a “system-wide” [49] view, when they are demanded into the
world of proteomics analysis that highly complex network and low abundance of
proteins are ubiquitous [50]. And proving a global view is the strength of the
mass spectrometry based proteomics approach for protein complexes.
In our lab, we combine HPLC with tandem mass spectrometry (MS/MS).
The mass spectrometry instrument in our lab, LTQ-Orbitrap Elite, provides
extremely highly mass solution, accuracy along with high sensitivity. In addition,
though stable isotope labeling approach increases reproducibility and reduces
instrumentation time, the method in this project, label-free approach, protects
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samples from chemical contamination originating from labeling agents [51].
Recently, we have developed this label-free approach and have discovered the
largest IRS1 interactome in human skeletal muscle and novel abnormalities in
IRS1 complexes in T2D [45].
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CHAPTER 2 RESEARCH DESIGN AND METHODS
The data in the project primarily derive from two mutually associated
aspects, clinical study and proteomics study (Fig 8a). In the clinical study, after
the participants were consented, comprehensive screening tests (Visit 1) were
performed to ensure eligibility of the participants. Eligible participants were
scheduled for the in-patient clinical test (Visit 2) which included hyperinsulinemiceuglycemic clamps with skeletal muscle biopsies (Fig 8b). The muscle biopsy
samples collected by clinical study were analyzed by proteomics as follows:
biopsy sample homogenization; PP1c co-immunoprecipitation; separating PP1c
and its interaction partners by 1D-SDS-PAGE gels; in-gel trypsin digestion and
peptide extraction; and HPLC-ESI-MS/MS protein analysis (Fig 8c). Appropriate
biological comparison and normal antibody IP are used in order to minimize false
positives. Pathway and function analysis were conducted on proteomics data by
bioinformatics analysis along with literature search, in order to identify pathways
enriched for PP1c interaction partners.

2.1. Materials
2.1.1 Antibody
Two kinds of PP1cα mouse monoclonal antibody (sc-271762 and sc-7482)
were purchased from Santa Cruz Biotechnology (Dallas, TX); PP1cβ rabbit
monoclonal antibody (ab53315) was purchased from Abcam (Cambridge, MA);
PP1cβ rabbit polyclonal antibody (07-207) was purchased from Upstate/Millipore
(Lake Placid, NY).
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2.1.2 Reagents
The following suppliers were used: sequencing-grade Modified trypsin
(Promega, Madison, WI); protein A sepharose , protein G-Agarose, and
iodoacetamide (Sigma, St Louis, MO); C18 ZipTip (Millipore, Billerica, MA);
Insulin ELISA Jumbo (AlPCO, Salem, NH).

2.2. Subjects
Nine lean, healthy volunteers were recruited and took part in the study at
the C. S. MOTT Clinical Research Center at Wayne State University. The
purpose, nature and potential risks of the study were explained thoroughly to all
participants, and written consent was obtained before their participation. All
participants received a 75 g oral glucose tolerance test on the same day when
the consent was obtained and screening tests were conducted to assess glucose
tolerance. None of the participants had any significant medical problems
(including diabetes), and none engaged in any heavy exercise, and they were
instructed to avoid any form of exercise for at least 2 days before the study. The
protocol was approved by the Institutional Review Board of Wayne State
University.

2.3 Hyperinsulinemic-Euglycemic clamp with muscle biopsies.
A hyperinsulinemic-euglycemic clamp was used to assess insulin
sensitivity and expose skeletal muscle to insulin in vivo, as previously described
[45, 52]. On the day of study, the study began at approximately 08:30 hours (time
-60 min) after a minimum 10-hour overnight fast. A catheter was placed in an
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antecubital vein and maintained throughout the study for infusions of insulin and
glucose. A second catheter was placed in a vein in the contra lateral arm, which
was covered with a heating pad (60°C) for sampling of arterialized venous blood.
Baseline arterialized venous blood samples for determination of plasma glucose
and insulin concentrations were drawn. At 09:00 hours (time −30 min) a
percutaneous needle biopsy of the vastus lateralis muscle was performed under
local anesthesia [53]. Muscle biopsy specimens were immediately blotted free of
blood, cleaned of connective tissue and fat (~30 sec), and then frozen in liquid
nitrogen. At 09:30 hours (time 0 min) a primed, continuous infusion of human
regular insulin (Humulin R; Eli Lilly, Indianapolis, IN) was started at a rate of 80
mU m-2 minute-1, and continued for 120 min. Plasma glucose was collected and
measured at 5-min intervals throughout the clamp. Euglycemia was targeted for
90 mg/dl by variable infusion of 20% d-glucose. At 11:30 hours (time 120
minutes), another muscle biopsy was obtained from the contralateral vastus
lateralis muscle.

2.4 Plasma insulin concentration determinations.
Plasma insulin concentration was measured by the ALPCO Insulin ELISA
Jumbo.

2.5 Proteomics sample preparation and analysis.
2.5.1 Muscle biopsy processing
Approximately

60–80

mg

frozen

muscle

biopsy

samples

were

homogenized in fridge using a Next Advance Bullet Blender (Model BBY5E) in
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detergent-containing lysis buffer A (50 mmol/l Hepes, pH 7.6, 150 mmol/l NaCl,
20 mmol/l NaPO4, 20 mmol/l β-glycerophosphate, 10 mmol/l NaF, 2 mmol/l
sodium vanadate, 2 mmol/l EDTA, 1% Triton, 10% glycerol, 2 mmol/l
phenylmethylsulfonyl fluoride (PMSF), 1 mmol/l MgCl2 , 1 mmol/l CaCl2,10µg/ml
leupeptin, 10µg/ml aprotinin) at a 100µl/10mg ratio. Biopsy specimens were
homogenized until no visible muscle remained (∼2×5min). Muscle lysates were
then incubated on ice for 15 min followed by centrifugation at 4°C for 20 min at
14× 1,000 rpm. Protein concentrations in the supernatant fractions were
determined by the Bradford protein assay (Bio-Rad, Hercules, CA) with BSA as
the standard [54].

2.5.2 Immunoprecipitation, 1D SDS-PAGE, in-gel digestion and mass
spectrometry
The lysate proteins were precleared with NIgG. A mixture of PP1cα and
PP1cβ antibodies coupled to both Protein A Sepharose and Protein G-Agarose
beads were used to immunoprecipitate PP1c with its interaction partners from
muscle lysate. The immunoprecipitates were spun down and washed three times
in 1 ml PBS solution. The remaining PBS solution was removed, the
immunoprecipitates were boiled in 15µl sample loading buffer, and the co-IP
proteins were resolved by 1D SDS-PAGE.
The whole SDS-PAGE gel lanes were excised, de-stained twice with
300µL of 50% acetonitrile (ACN) in 40 mM NH4HCO3 and dehydrated with 100%
ACN for 15 min. After removal of ACN by aspiration, the gel pieces were dried in
a vacuum centrifuge for 30 min. Trypsin in 20µL of 40mM NH4HCO3 was added
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and the samples were maintained at 4 °C for 30 min before the addition of 50µL
of 40mM NH4HCO3. The digestion was allowed to proceed at 37 °C over-night
and was terminated by addition of formic acid (FA). After further incubation, each
supernatant was transferred and the extraction procedure was repeated by
replenishing new solution with low FA concentration, and the two extracts were
combined. The resulting peptide mixtures were purified by C18 ZipTip after
sample loading in buffer containing peptides to serve as internal standards [55].
On-line HPLC on a Linear Trap Quadrupole-Orbitrap Elite (LTQ-Orbitrap Elite)
was

performed

as

described

previously

[56]

with

instrument

specific

modifications.

2.5.3 Sample data analysis
Using

the

MaxQuant

software,

peptides/protein

identification

and

quantification were performed, and peak areas for each protein were obtained by
LFQ analysis. Only proteins identified with minimum 2 unique peptides and with
false discovery rate (FDR) at 0.01 were considered. To be considered as a bona
fide PP1c interaction partner, a protein has to further satisfy following criteria
[45]: a). With an enrichment ratio >10 (Fig. 9); b). Identified with LFQ peak area
(PA) in more than half of the PP1c IP (i.e. >9 out of 18 biopsies used). The
enrichment ratio was calculated as follows:
1st, PA for a protein identified in a gel lane was normalized against the sum of the
peak areas for all proteins identified in the same gel lane to obtain normalized
ratio for each protein, Norm:i,
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Norm:  

PA
∑ PA

Then, the average of normalized ratio for each protein in the PP1c coimmunoprecipitates, Average_Norm:i_PP1c, as well as the average of
normalized ratio for the same protein in the NIgG co-immunoprecipitates,
Average_Norm:i_NIgG, were obtained. Finally, Average_Norm:i_PP1c was
divided by Average_Norm:i_NIgG, to obtain the enrichment ratio for each protein.

Enrichment_Ratio:  

Average_Norm: _PP1c
Average_Norm: _NIgG

Since we used NIgG as a control, the first level of identification will be to search
for proteins exclusively detected in the PP1c immunoprecipitates. However, this
will result in false negatives. Due to the high sensitivity of our approach, even if a
trace amount of a protein was non-specifically absorbed on the NIgG beads, it
may be identified with minimum 2 unique peptides with FDR at 0.01.
Nonetheless, if this protein is a true component of the PP1c complex, higher
peak area will be assigned to this protein in the PP1c sample than in the NIgG
sample.
To determine the relative quantities of PP1c interaction partners in lean,
healthy subjects, the PA for each protein identified in a specific biopsy was
normalized against the PA for PP1c identified in the same biopsy, which results
in Norm:j.

Norm:  

PA
PA_PP1c
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The normalization strategy is widely used in proteomics studies involving proteinprotein interactions [57], and uses the same concept used in Western blotting.
The normalized peak area for each PP1c interaction partner, Norm:j, was
compared within the group to assess effects of insulin.

2.5.4 Statistical analysis
Although thousands of proteins were assigned in at least one of 18
biopsies that were detected, a series of filters were used to narrow the number of
proteins that were used to assess effects of insulin in lean healthy controls as
described above. Statistical significance was assessed using Z-test. Differences
were considered statistically significant at p<0.05*.

2.5.5 Bioinformatics analysis
Pathway analysis on PP1c interaction partners were performed using
Ingenuity Pathway Analysis (Ingenuity Systems, Inc., Redwood City, CA), which
considers a pathway to be a set of genes. IPA software package is widely used
and contain biological and chemical interactions and functional annotations
created by manual collection of the scientific literature [58]. A pathway was
considered as significantly enriched if both the false discovery rate (FDR) for the
pathway was less than 0.01 and the pathway included at least 4 of the identified
PP1c partners.
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CHAPTER 3 RESULTS
Clinical information of participants in the project is shown in Table 1.
Criteria indicating the state of diabetes are shown in the table, namely 2h OGTT
Glucose level, HBA1c percentage, and Fasting plasma glucose level, manifesting
the values within healthy, non-diabetes range.
PP1cα and PP1cβ were detected in PP1c immunoprecipitates from all 18
biopsies used for the study, but were not detected at all in the NIgG
immunoprecipitates. In total, 46 proteins met the criteria for classification as
PP1c interaction partners (Table 2). Note that PP1c interaction partners listed in
Table 2 may involve both direct interaction partners, and indirect partners
through other proteins that interact with PP1C directly. Among these 46 PP1c
interaction partners, 31 partners were previously unreported in any species.
Among the 15 proteins were previously reported as PP1c interaction partners,
only 3 were reported in human skeletal muscle (Table 2). IPA pathway analysis
on the 46 PP1c interaction partners manifested that multiple pathways are
significantly enriched, such as pathways related to mitochondrial function, insulin
signaling, protein synthesis and degradation, and cytoskeleton dynamics (Fig
10A and Table 3). These results imply that PP1c participates in these biological
processes or that PP1c is a downstream target regulated by these pathways. A
significantly enriched interaction network of PP1c (EIF2 Signaling) is shown in
Fig 10B. These novel PP1c interaction partners in humans may be a reference of
the various roles that PP1c plays in physiological normal conditions in skeletal
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muscle and other tissues/organs. It also provides a control for PP1c interaction
partner researches in insulin resistance and T2D.
Among 46 interaction partners, 8 showed significant change in their
interaction to PP1c between basal (without insulin-infusion in vivo in humans)
and insulin (after 2 hour insulin-infusion in vivo in humans) biopsies; 6 of them
significantly increased, and other 2 decreased. In addition, 23 interaction
partners show 1.3 fold, non-significant change after insulin stimulation (among
them, only one had decreased association with PP1c). Please see Table 2 for
details.
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CHAPTER 4 DISCUSSION
During the past decade, genomics and transcriptomics studies have
revealed

valuable

information

regarding

mechanisms

underlying

insulin

resistance and T2D. However, the abundance of proteins and protein-protein
interactions may not be assessed directly using genomics and transcriptomics
[59]. HPLC-ESI-MS/MS based proteomics has emerged as a prevailing means
for investigating protein-protein interaction networks in insulin resistance. PP1c
interaction partners are large in number and widespread in various tissues and
cell types. However, most studies on PP1c protein-protein interactions have been
performed in cell culture or animal models. No PP1c interactome in human
skeletal muscle tissue has been reported yet. The present project determined
interacting partners of PP1c in muscle biopsies of lean healthy participants using
the proteomics approach recently developed in our group [45]. The proteomics
approach includes NIgG immunoprecipitation as a negative control to determine
non-specific binding, multiple biological comparisons to improve confidence, and
bioinformatics analysis to identify significantly enriched pathways. The strategy
detects endogenous protein complexes, without using labeling or protein
overexpression/ tags [45], may be applicable to other protein complexes in cells,
animal models, and in human tissue samples [45]. Using this approach, we have
identified 46 PP1c interaction partners in multiple functional pathways in small
skeletal muscle biopsies from human participants. These interaction partners are
discussed below.
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4.1 PP1c Interaction Partners as PP1 regulatory proteins
PPP1R2/PPP1R2P3 protein group
Protein phosphatase inhibitor 2 (PPP1R2), used to be called as I-2, was
one of the first PP1c inhibitors discovered. In contrast to the other PP1c
inhibitors, PPP1R2 inhibits PP1c by competitive inhibition. Unlike PPP1R1 and
DARPP-32, classical PP1c RVXF binding motif is not seen in sequence of
PPP1R2, which suggests that PPP1R2 interacts with PP1c in a different way with
PPP1R1 and DARPP-32 [60]. Despite extensive studies, the physiological role
and mechanism of PPP1R2 remain elusive. Interestingly, PPP1R2 has been
report to induce centrosome separation [61], and fluctuation of PPP1R2 protein
and mRNA levels during the cell cycle is observed [62]. PPP1R2 was first
discovered in 1976 in rabbit skeletal muscle [63]. Though it is ubiquitous
expressed, no research has shown its function and interaction partners in human
skeletal muscle.
Protein phosphatase 1, regulatory (inhibitor) subunit 2 pseudogene 3
(PPP1R2P3) was previously thought to be a pseudogene. However, it has been
recently identified at the protein level [64]. It has similar function with PPP1R2
and shares 95% sequence identity with PPP1R2 [64]. The peptides identified by
HPLC-ESI-MS/MS were shared between PPP1R2/PPP1R2P3.
Protein phosphatase 1 regulatory subunit 3A and 3B (PPP1R3A, PPP1R3B)
PPP1R3A and PPP1R3B are glycogen-associated regulatory subunits of
PP1c, PP1-GTSs, which direct PP1c to the glycogen particles. Several other
members exist in PP1-GTS family. However, members in this family are not
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characterized by their low sequence identity, but by glycogen-binding domain
[65]. Both PPP1R3A [66] and PPP1R3B [67] have been reported to interact with
PP1c in human skeletal muscle. PPP1R3A specific expressed in myocytes, while
PPP1R3B can express both in muscle and in liver [65].
Protein phosphatase 1 regulatory subunit 7 (PPP1R7).
PPP1R7 is homolog of Schizosaccharomyces pombe gene sds22 in
humans. It is expressed in a variety of tissues in humans, including skeletal
muscle [68]. In S. pombe studies, it is clear that sds22 regulates chromosome
segregation during mitosis [69]. PPP1R7 also involves in regulation of cell shape
and myosin phosphorylation state [70].
Nuclear inhibitor of protein phosphatase 1 (PPP1R8)
PPP1R8, also commonly known as NIPP1, is one of the evolutionarily
oldest PP1 regulators. PP1c interaction complexes with PPP1R8 possess more
than one-third of the nuclear pool of PP1 holoenzyme [71]. PPP1R8 was
originally identified as a PP1 inhibitor because binding of NIPP1 inhibits the
dephosphorylation

of

canonical

PP1

substrates,

including

glycogen

phosphorylase a [72]. Although mechanism of functions of PP1-PPP1R8
complex remains uncertain, it is reported that the complex binds RNA to exert
endoribonuclease activity [73]. Other functions that associate to the complex
include

transcription,

pre-mRNA

splicing,

cell-cycle

progression,

and/or

chromatin remodeling [72]. PP1-PPP1R8 complex targets a number of
substrates, including the pre-mRNA-splicing factor SF3B1, a component of the
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U2 snRNP that recruits the complex to the spliceosome [74]. Intriguingly, SF3B1
has also been found as an interaction partner in this research (Table 2).
Protein phosphatase 1 regulatory subunit 11 (PPP1R11),
PPP1R11, also known as Inhibitor-3 of PP1c, is a small protein that is
conserved evolutionarily. PPP1R11 is localized to the nucleoli and centrosomes
by regulation of different PP1c isoforms. A significant portion of the cellular pools
of PP1α and PP1γ1 that are associated with PPP1R11 is reported, suggesting
that PPP1R11 may modulate cellular pool distribution and subcellular localization
of these isoforms [75]. Though still being unclear, cellular functions of PPP1R11
are likely to be associated with nuclear regulation of PP1 and with the regulation
of cell division [76]. PPP1R11 may also have a role in apoptosis [77]. In
mammalian cells, PPP1R11 is hetero-terpolymerized with PP1c and PPP1R7, a
PP1 regulatory subunit that is involved in mitosis and chromosome segregation
processes [78]. Interestingly, PPP1R7 has also been found as an interaction
partner in this research (Table 2).
Protein phosphatase 1 regulatory subunit 12B (PPP1R12B)
PPP1R12B, also known as MYPT2, forms complex with PP1cβ.
PPP1R12B is expressed preferentially in heart, brain and skeletal muscle, while
another member in MYPT family, MYPT1 (PPP1R12A) expresses mainly in other
cell types such as smooth muscles [79]. PPP1R12B is involved in muscle
contraction, cardiac torsion, and organization of sarcomere [80]. Interestingly,
PPP1R12B, as well as PPP1R12A, has been found to associate with insulin
signaling. Pham et al. [81] reported previously that PPP1R12B phosphorylation is
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responsive to insulin stimulation, indicating PPP1R12B may be involved in insulin
signaling. Geetha et al. [82] reported that in L6 cells, PPP1R12A/PP1cβ may
involve in insulin signaling depending on Akt and mTOR/raptor activation.
Phosphatase and actin regulator 4 (PHACTR4)
PHACTR4 is a PP1 regulatory protein, mediating both PP1 and actin
binding. Protein members in PHACTR family have been implicated in many
distinct biological processes depending on actin cytoskeleton, including
angiogenesis, cell spreading, migration and axon elongation. PHACTR4 is
reported to interact with PP1c by yeast two hybrid [83]. The PHACTR4 mutation
cannot interact with PP1, resulting in cell cycle regulation abnormality. Actin
binding to PHACTR4 competes with PP1 binding and consequently the PP1c
phosphatase activity is determined by the ratio of monomeric and polymeric actin
in cells [84].

4.2 PP1c Interaction Partners involved in cytoskeleton dynamics
ACTB/ACTG1 protein group
Actin β and γ1 are actins. Actin is one of the well- studied proteins in cells.
There are 6 actin isoforms: 4 muscle actins, 2 cytoplasmic actins. Beta- and
Gamma actin are cytoplasmic actins. Beta- and Gamma actin are nearly identical
(differ by only 4 amino acids), and the peptides identified by HPLC-ESI-Ms/MS
were shared by these two proteins. Generally, actin plays an important role in
cytoskeletal structure, cell mobility and cell morphology [85] [86]. However,
distinct co-localization patterns and function occurs among isoforms. To be
specific, beta-actin localizes near the leading edges in several cell types, and it
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may elicit essential function in neuronal development. Gamma actin can be
detected in filament structure encircling mitochondria. Unlike beta isoform,
gamma actin distributes evenly in fibroblasts. ACTB knockout is lethal mutation,
while ACTG1 knockout is not [85] [86]. Actin beta and gamma1 is reported to
interact with PP1c in cell model [87] and in rat tissues [88]. ACTB mRNA is
regulated by insulin in human skeletal muscle [89].
Prothrombin (F2)
F2 is one of the coagulation factors that functionally relates to vascular
endothelial growth factors [90]. It has also been reported that F2 stimulates actin
contraction in LM8 cell lines [91].
LIM and cysteine-rich domains protein 1(LIMCH1)
LIMCH1 contains both LIM and Calponin homology domains, so that it
may function as cytoskeletal organization [92] and/or actin binding [93].
Prolactin-inducible protein (PIP)
PIP is small in size and plays multiple important functions. It has ability to
bind potentially with CD4-T cell receptor, immunoglobulin G (IgG), actin, zinc α2glycoprotein (ZAG), fibronectin and enamel pellicle, revealing its importance in
biological functions [94].
Erythrocyte band 7 integral membrane protein (STOM),
STOM, also known as stomatin, shows co-localization with actin
microfilaments in epithelial cells [95]. STOM is located in protruding structures in
plasma membrane and it forms homo-oligomers in the human epithelial cell,
suggesting that this protein participates in the cortical morphogenesis of the cells
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[96]. However, other roles of STOM in cells are still in opaque, e.g.
overexpression of STOM negatively affects activity of GLUT-1 glucose
transporter [97].
TRIO and F-actin-binding protein (TRIOBP)
TRIOBP has three isoforms, but only TRIOBP-1 is ubiquitously expressed.
Cellular structure functions by directly binding F-actin as well as associating with
the trio rho guanine nucleotide exchange factor to regulate actin filament
organization [98] and adherens junctions [99] in cells.

4.3 PP1c Interaction Partners in mitochondrial function
Isobutyryl-CoA dehydrogenase, mitochondrial (ACAD8)
ACAD8 is one of the flavoproteins. The encoded protein is a mitochondrial
enzyme that functions in catabolism of the branched-chain amino acid valine
[100]; Defects in this gene are the cause of isobutyryl-CoA dehydrogenase
deficiency [101]. ACAD8 is reported to interact with PP1c by yeast two hybrid
[83].
Estradiol 17-beta-dehydrogenase 8 (HSD17B8)
HSD17B8 namely, 17 beta-HSD8, was previously classified as a steroidmetabolizing enzyme [102], but recent data suggest that HSD17B8 is primarily
involved in mitochondrial fatty acid synthesis [103].
Metaxin 2 (MTX2)
MTX2 is bound to the mitochondrial outer membrane at the cytosolic face
by its interaction with membrane-bound metaxin 1. This complex may play a role
in protein importation into mammalian mitochondria [104].
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Pentatricopeptide repeat-containing protein 1 (PTCD1)
PTCD1 is a mitochondrial matrix protein that associates with leucine
tRNAs and precursor RNAs that contain leucine tRNAs [105].
Mitochondrial import inner membrane translocase subunit TIM50 (TIMM50)
TIMM50 encodes Tim50 protein that is a Subunit belonging to TIM23
Complex. The TIM23 complex links protein translocation across the Outer and
Inner membranes of mitochondria [106]. The existence of a CTD-like
phosphatase domain in human Tim50 suggests that Tim50 might exert a
serine/threonine phosphatase activity in vitro [107]. Intriguingly, this phosphatase
activity is not conserved evolutionarily. The phosphatase activity shows in TIM50
homolog in Trypanosoma brucei, a parasitic protozoan; while it is not in Fungal
Tim50 [108].
Uveal autoantigen with coiled-coil domains and ankyrin repeats (UACA)
UACA is an Autoantigen that is regulated by insulin in human skeletal
muscle [89]. Autoantigen may be attacked by autoimmunity which leads to VogtKoyanagi-Harada disease [109] or Graves’ disease [110]. The mouse ortholog of
UACA may play some roles in cardiac muscle development, cytoplasm,
especially around the nuclear membrane and mediates apoptosis [111].

4.4 Interaction Partners act in metabolism pathways
Very

long-chain

specific

acyl-CoA

dehydrogenase,

mitochondrial

(ACADVL)
ACADVL acts on its substrate on 14-24 carbon chain length with optimum
activity for palmitoyl-CoA (C16-CoA) in β-oxidation in skeletal muscle [112].
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Caveolin-1(CAV1)
CAV1 is an integral membrane protein with multiple functions. The
preferred location for caveolin-1 is the caveola at the cell surface. It involves in a
number of cellular functions. The most common function for caveolin-1 is to be a
lipid transporter. Cholesterol is required for lipid transportation of caveolin-1, and
caveolin-1 also binds to long chain unsaturated fatty acids to facilitate its
transportation [113]. Caveolin-1 not only transports lipids, but also conducts
membrane traffic of other components [114]. Moreover, though most researchers
believe caveolin-1 to be a scaffold protein, some reports show activation of EGF
pathway leads to down-regulation of caveolin-1, which may aggravate tumor
invasion ability [115]. Finally, caveolin-1 acts as an activator of insulin signaling
[116], and caveolin-1 deficient mice have been shown to be insulin resistance
[117]. Caveolin-1 has been shown to interact with PP1 in prostate cancer cell
models [118].
3-methyl-2-oxobutanoate dehydrogenase kinase, mitochondrial (BCKDK)
The mammalian mitochondrial branched-chain α-keto acid dehydrogenase
(BCKD)1 complex conducts catalysis of the oxidative decarboxylation structure of
branched-chain α-keto acids to bring about branched-chain acyl-CoAs formation.
The reaction products indirectly associate with the Krebs cycle or linked to lipid
biosynthesis. BCKDK is the kinase that regulate this process [119].
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Cystatin-B (CSTB)
CSTB has been suggested to counteract inappropriate proteolysis of the
cell due to cathepsins that leak out of the lysosomes, but CSTB may also interact
with other cellular proteins [120].
PDZ domain-containing protein GIPC1 (GIPC1)
GIPC1 is a G-couple protein. In L6 myoblast cells, GLUT1/GIPC1
interaction increases with enhanced GLUT1 activity, which may participate in
glucose uptake regulation [121].

4.5 Interaction Partners relate to Protein Synthesis and
Degradation,
Splicing factor 3B subunit 1 (SF3B1)
SF3B1 also known as Sap155, belongs to U2 spliceosomal RNA (snRNP)
that is a component of spliceosome. Spliceosome processes precursor mRNAs
into mature mRNA by splicing intron. Posttranslational protein modification,
especially phosphorylation state, is critical for splicing dynamics, e.g. SF3B1 is
hyperphosphorylated before and dephophosphorylated after step 1 of splicing
[122]. It has also been reported that in HTO cells, dephophosphorylation activity
of SF3B1 is conducted by Protein Phosphatase 1, regulated by Nuclear Inhibitor
of Protein Phosphatase-1 (NIPP1, also known as PPP1R8) [123]. This is
considered as an evidence that PP1 involves in regulation of transcription and
protein synthesis.
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Heterogeneous nuclear ribonucleoprotein Q (SYNCRIP)
As mentioned above, pre-mRNA converts into mature mRNA by
spliceosomes. However, another group of proteins, Heterogeneous nuclear
ribonucleoproteins (hnRNPs), involves before and after pre-mRNA processing.
hnRNPs prevent pre-mRNA forming a short secondary structure, leading to
better accessibility for interactions. In addition, hnRNPs function as mRNA
transporter that assists mature mRNA to transport out to cytoplasm [124].
Research has shown that the cytoplasmic RNA-binding protein, SYNCRIP, was
highly homologous to heterogeneous nuclear ribonucleoprotein R (hnRNP R).
SYNCRIP binds to RNAs with preference to poly-(A) RNA. Nevertheless,
distribution of SYNCRIP is predominantly in the cytoplasm, while the nuclear
localization is shown in hnRNP R [125]. Like hnRNPs, SYNCRIP function as a
stabilizer of mRNA [126]. SYNCRIP has been shown to interact with PP1 in cell
models [87].
Transformer-2 protein homolog beta (TRA2B)
The serine- and arginine-rich protein (SR protein) of RNA binding proteins
plays an important role in both constitutive and alternative pre-mRNA splicing. It
is known to be a molecule that involves in both protein–protein and protein–RNA
interactions. These interactions are important for RNA metabolism. As a member
of SR protein family, TRA2B structurally associates with the classical SR proteins
and functionally involves in regulating alternative splicing pathways. Mammalian
TRA2B has been shown to influence tissue specific functions by appropriate
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alternative splicing [127]. An in vitro study has shown the interaction between
TRA2B and PP1 [128].
39S ribosomal protein L49 (MRPL49)
MRPL49 is a component in human mitochondrial ribosomes [129].
DNA-directed RNA polymerase II subunit RPB3 (POLR2C)
POLR2C is a subunit of RNA polymerase II. In eukaryotic cells,
transcription of protein coding genes is accomplished by RNA polymerase II,
associating with a number of cofactors. These cofactors control the selectivity
and efficiency of transcription initiation, elongation and finally termination [130].
DNA-directed RNA polymerase II subunit RPB1 (POLR2A)
POLR2A is another component of RNA polymerases that functions to
remove the phosphates from the RNA polymerase II carboxyl-terminal domain.
RNA polymerases are recruited to target gene, forms a transcription complex,
and initiates transcription process. In eukaryotes, three types of RNA polymerase
exist, each of which targets different RNAs. RNA polymerase II participates in
transcriptions of all protein-coding genes, producing mRNA [124]. Insulin
stimulation on skeletal muscle increases in the muscle transcript levels [131],
which putatively increases RNA polymerases II activity. Furthermore, RNA
polymerases II binds to PPARγ, a transcriptional activator in adipocytes, when it
transcribes genes involved in lipid synthesis, lipids storage, cell growth, insulin
signaling, and adipokine production [132]. This protein has been found in vitro to
interact with PP1c [133].
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Protein quaking (QKI)
QKI is an RNA binding protein that regulates embryogenesis, blood vessel
development, glial cell fate determination, and apoptosis [134].
RNA-binding protein Raly (RALY)
RALY is a member of the heterogeneous nuclear ribonucleoproteins, a
family of RNA-binding proteins generally involved in many processes of mRNA
metabolism [135].
Ribosomal proteins: RPL14, RPL18A, RPL3L, RPS11, RPS25, and RPS9
The ribosome is a large and complex molecular machine that serves as
the primary site of biological protein synthesis [136]. Ribosomes are large
ribonucleoprotein complexes that provide an accurate structure for mRNA
translation and protein synthesis [137]. The eukaryotic ribosome includes four
ribosomal RNA (rRNA), and large numbers of ribosomal proteins (RP) [138]. This
complex exhibits a very huge molecular mass and a sedimentation coefficient of
80S. The ribosome is composed of two major subunits; a small subunit involved
in decoding of the mRNA and a large subunit that embraces the peptidyl
transferase center which is buried in the rRNA. In eukaryotes, the 40S small
subunit is composed of only one 18S rRNA, whereas the 60S large subunit
contains three rRNA (5S, 5.8S and 28S) [137]. Among the list of ribosomal
proteins in this study, RPS11, RPS25, and RPS9 belongs to 40s subunit while
RPL14, RPL18A, and RPL3L belongs to 60s subunit [137, 139].
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Double-stranded RNA-binding protein Staufen homolog 2 (STAU2)
STAU2 is regulated by insulin in human skeletal muscle [89]. Function of
STAU2 includes binding of double-stranded RNA, transport of RNAs in neuron,
degradation of specific mRNAs contains STAU-binding site 1 [140].
Transcription elongation factor B polypeptide 2 (TCEB2)
TCEB2 is a component of E3 ubiquitin ligase, conduct ubiquitination [141].
It serves a chaperone-like function, facilitating assembly and boosting stability of
the Elongin (SIII), a complex activates translational elongation process by
mammalian RNA polymerase II. The elongation process is initiated by minimizing
transient pausing of the polymerase within transcription units [142].
Probable tRNA pseudouridine synthase 2 (TRUB2),
TRUB2 also known as TruB, is an RNA pseudouridine synthase which
catalyzes pseudouridine formation in tRNA. This posttranscriptional modification
is evolutionary conserved [143]. Another member in TRUB family, TRUB1, is
widely expressed in various human tissues (especially heart, skeletal muscle and
liver). TRUB2 gene was also found in human genome, however, much of the
study on TRUB2 function based on bacterial TruB/psi55, a homolog of TRUB2
[144].

4.6 Other PP1c Interaction Partners
Asporin (PIGR)
Asporin inhibits chondrogenesis and blocks TGF-β1-induced expression of
matrix genes and the resulting chondrocyte phenotypes [145].
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Polymeric immunoglobulin receptor (PIGR)
This polymeric immunoglobulin receptor is normally transferred from the
Golgi to the basolateral surface in epithelial cells and shows function in immune
system by transporting polymeric IgA and IgM to the apical surface.
LIM and cysteine-rich domains protein 1 (LMCD1)
LMCD1 is regulated by insulin in human skeletal muscle [89]. It interacts
with TGFβ1 [146]. In cardiomyocytes, LMCD1 combines with Dyxin to form a
complex, which will activate PP3 [147] or GATA6 [148] to regulate transcription
factors. Since it interacts with PP3, another member of PPP family, it is not
surprise to see it interacts with PP1. LMCD1 contains LIM domain, indicating that
multiple functions may associate with LMCD1: actin regulation, Integrin
regulation, and Cell-fate decision [149].
Lactotransferrin (LTF)
LTF is involved in muscle hypertrophy and myogenesis [150]. Originally, it
was consider as a secretory iron-binding protein that can inhibit bacteria growth
[151].

4.7 Influence of Muscle Fiber-type Composition
It is reported that type I, type IIa, and type IIx muscle fibers exist in human
skeletal muscle [152], and significant variability has been shown between
different ages [153], sexes [154], and individuals [153] [154]. Type IIx and IIa
fibers are fast twitch fibers and type 1 fibers are slow twitch fibers. Proportion of
fast and slow twitch fibers correlate with glucose metabolism and muscle insulin
sensitivity [155], and it is possible that differences in muscle fiber type may lead
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to unexplained variability in the protein interaction partners in the muscle biopsy
samples.
Therefore, we plan to measure muscle fiber composition as described in
the manuscript [156] for future studies. By assessing skeletal muscle fiber-type
composition, we will be able to determine whether any observed differences in
our major outcomes (e.g., differences in PP1c interaction partners) are related to
differences in muscle fiber composition.

4.8 Summary
In this study, 46 proteins have been identified as PP1c interaction partners
in human skeletal muscle in lean, healthy participants. And 8 of them express
significant change after insulin stimulation (including ASPN, PIGR, POLR2A,
PPP1R3A, PPP1R3B, PPP1R8, PPP1R12B, and RPS9). This study provides a
list of PP1c interaction partners as reference for future studies in phosphatase
biology, in interactome analysis, and in diabetes research. The successive step
of this study will be validating of these interaction partners, and studying those
partners showed significant changes upon insulin stimulation to determine
whether insulin responsiveness of these PP1c partners would be diminished in
type 2 diabetic patients.
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Environmental Factors
Lifestyles and Food Intake

Obesity / Insulin
resistance Genes

Insulin Responsive Tissues:
·

Liver

·

Adipose tissue

·

Skeletal Muscle

Obesity
Insulin resistance

Pancreatic β cell

Glucose Uptake
decrease

β cell dysfunction

Hyperglycemia

Insulin secretion
decrease

Type 2 Diabetes

Figure 1. The causal relationship and tissue involvement of Type 2 Diabetes
development.
Mutual interaction between genes and environmental factors (food intake and exercise
habits) is a decisive factor of body shape and insulin sensitivity. Insulin resistance in
insulin responsive tissues affects glucose uptake rate, resulting in the blood glucose
increase. Hyperglycemia, as well as insulin resistance will progressively damage β cells,
eventually leading to Type 2 Diabetes.
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Insulin

GLUT4

PIP2

IRS-1

PIP3

Y

S/T

PI3k

PDK1

Glycogen Synthesis
Protein Synthesis
Gene Expression

GLUT4 vesicles

Glucose Uptake

AKT
AS160

Figure 2. Overview of signal molecules involved in insulin signaling pathway.
Binding of insulin with insulin receptor initiates PI3k pathway, mediated by IRS-1
IRS in
skeletal muscle. PI3k pathway activates AKT (PKB), a molecule participates in multiple
functions, including glucose uptake.
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Figure 3. The sequence of three major isoforms of PP1c: PPP1CA isoform 1,
PPP1CB, PPP1CC isoform 1.
Asterisks mark identical positions shared by three isoforms. Colons and dots indicate
residues share similarity. Identical residues have been highlighted in yellow. Isoform
alpha and beta, alpha and gamma, beta and gamma share 89.7%, 89.8%, and 85.7%
identity, respectively. Sequence data come from NCBI. Analyzed by the ClustalX 2.1
Align tools.
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A

Figure 4. Structure information of PP1c
A.3D structure of human Protein Phosphatase 1 catalytic subunit, isoform α. Structure
showed in ribbons indicates hydrophobicity - hydrophilic amino acids (yellow) and
hydrophobic amino acids (orange).Catalytic core has been shown in atoms: Carbon
(grey), Oxigen (red), Nitrogen (white), and Manganese (purple). Note that two Mn ions
are critical for catalytic activity of PP1c. Structure information came from [157]. The
figure creates by Jmol: an open-source Java viewer for chemical structures in 3D
(http://www.jmol.org/);
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B

Figure 4. Structures of PP1c
B. Motif analysis of PP1c. Catalytic core is illustrated in purple; Metal binding sites are
illustrated in red; and Interaction binding sites are illustrated in blue. Number of amino
acid in sequence marked in the figure [30, 32, 33].
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Figure 5. Interactions between PP1c and its interaction partner, MYPT1 to form a
PP1 holoenzyme.
PP1c δ (up left) and PP1 regulatory subunit (up right) forms a complex (down) to
achieve substrate specificity. The confluence of three binding groove (yellow lines) is
catalytic core of PP1c. Reproduced with permission from [158].
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Figure 6. Regulation patterns of interaction partners on PP1c
Mechanisms by which interaction partners interact with PP1c include: (i) control PIP
proteolysis; (ii) phosphorylation state affects association; (iii) Recruitment of inhibitors;
(iv) Allosteric regulation; (v) Binding with 14-3-3 protein masked substrates; (vi)
Competition for the same binding sites. Reproduced with permission from [31].
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Figure 7. Summary of glucose metabolism change in Type 2 diabetes among
different tissues during euglycemic insulin clamp studies.
Net glucose uptake is similar (Liver and Adipose tissue) or unaffected by
hyperinsulinemia between healthy and T2D individuals. Muscle glucose uptake in
healthy individuals accounts for approximately 75%–80% of total glucose uptake. In T2D
patients, the most remarkable reduction in insulin-mediated glucose uptake is observed
in muscle glucose disposal. Reproduced with permission from [159].
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Figure 8A

Figure 8A. General flow chart of clinical and proteomics data acquisition and
analysis;
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Figure 8B

Figure 8B. Detailed illustration of clinical visit2
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Proteins other than PP1c identified with minimum 2 unique peptides
with FDR at 0.01 in at least one PP1c IP?
(1260 proteins)

Enrichment ratio for each protein determined. Enrichment ratio for a
protein > 10 (PP1c vs NIgG IP)?
(421 proteins)

Identified with LFQ peak area (PA) in more than half (e.g., > 9 out of
18) PP1c IP samples?
(46 proteins)

With a fold change over basal greater than 1.3 (i.e., 1.30 fold increase)
or less than 0.77 (i.e., 1.30 fold decrease)?
(31 proteins)

P<0.05 by independent Z-tests?
(8 proteins)

Figure 9. Detailed Proteomic Analysis workflow
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Figure 10. Network analysis of enriched PP1c interaction partners in human
skeletal muscle revealed by proteomics and Ingenuity Pathway Analysis.
Analysis
All parameters were set as default, with the exception of the number of molecules per
network was maximized to 35. The top scored network (score at 51), which is related to
Carbohydrate Metabolism, was shown, which contained 21 molecules derived from the
list of 46 interaction partners identified in this study. PP1c is highlighted in purple, PP1c
partners with 1.3 fold inc
increased interaction with PP1c upon insulin--infusion are
highlighted in green (significant increase
increase, P<0.05) or blue (insignificant increase,
P≥0.05),, partners significant
significantly decreased are highlighted in red, and partners shows no
change in this study are hig
highlighted in grey, respectively.. Solid and dashed connecting
lines indicate the presence of direct and indirect interact
interactions
ions in the Ingenuity database,
respectively.
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Figure 11A
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Figure 11. Significantly enriched pathways for the PP1c interaction partners
identified in this study revealed by Ingenuity Pathways Analysis. A). Significantly
enriched pathways. The total number of identified PP1c interaction partners for a given
pathway in this study is denoted beside each bar. B) PP1c interaction partners in EIF2
Signaling.
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Figure 11B

Figure 11B. PP1c interaction partners in EIF2 Signaling
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Table 1. Clinical characteristics participants in the PP1c interaction partner study.
Results were shown as mean ± SEM. Normal values are in Bold after BMI, 2h OGTT
glucose, HBA1c, and Fasting plasma glucose values.

9 participants in lean group
Gender (M/F)

(5/4)

Age (years)

35.9 ± 3.3

2

BMI (kg/m )

23.8 ± 0.7 (< 25)

2h OGTT Glucose (mmol/l)

5.5 ± 0.3

2h OGTT Glucose (mg/dl)

98.7 ± 6.1 (<140)

HBA1c (%)

5.2 ± 0.1 (<5.7)

Fasting plasma glucose (mmol/l)

4.5 ± 0.1

Fasting plasma glucose (mg/dl)

81.2 ± 1.7 (<100)

Fasting plasma insulin (pmol/l)

29.8 ± 2.9

M-value (mg/kg/min)

8.8 ± 1.0
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Protein

Gene names

mean fold change
over basal

Table 2 The 46 proteins/ protein groups met the 2 rigorous criteria (See Methods
for details) for classification as PP1c interaction partners in human skeletal
muscle.

Asporin

ASPN

3.27±1.10*

PIGR

5.59±1.79*

PPP1R3A

1.36±0.15*

PPP1R3B

1.43±0.20*

PPP1R12B

1.52±0.26*

RPS9

1.89±0.41*

ACAD8

3.89±1.78

ACADVL

2.35±1.32

Actin, cytoplasmic

ACTB;ACTG1

6.03±4.54

3-methyl-2-oxobutanoate
dehydrogenase kinase,
mitochondrial

BCKDK

1.88±0.69

Caveolin-1

CAV1

2.66±1.40

Cystatin-B

CSTB

1.32±0.57

Prothrombin

F2

1.67±0.40

PDZ domain-containing protein
GIPC1

GIPC1

1.96±0.77

Polymeric immunoglobulin
receptor
Protein phosphatase 1 regulatory
subunit 3A
Protein phosphatase 1 regulatory
subunit 3B
Protein phosphatase 1 regulatory
subunit 12B
40S ribosomal protein S9
Isobutyryl-CoA dehydrogenase,
mitochondrial
Very long-chain specific acyl-CoA
dehydrogenase, mitochondrial

55

Protein

Gene names

mean fold change
over basal

56

LIM and calponin homology
domains-containing protein 1

LIMCH1

1.96±0.92

Lactotransferrin;Kaliocin-1

LTF

1.70±0.96

39S ribosomal protein L49

MRPL49

1.39±0.49

POLR2C

2.95±1.56

PPP1R7

1.50±0.53

PTCD1

1.39±0.51

Protein quaking

QKI

1.34±0.32

RNA-binding protein Raly

RALY

1.30±0.51

60S ribosomal protein L18a

RPL18A

8.05±6.87

60S ribosomal protein L3-like

RPL3L

3.21±1.68

Semenogelin-1;Semenogelin-2

SEMG1;SEMG2

1.37±0.59

TCEB2

1.43±0.39

TIMM50

1.68±1.12

TRIO and F-actin-binding protein

TRIOBP

1.64±0.34

Uveal autoantigen with coiled-coil
domains and ankyrin repeats

UACA

1.52±0.41

DNA-directed RNA polymerase II
subunit RPB3
Protein phosphatase 1 regulatory
subunit 7
Pentatricopeptide repeatcontaining protein 1

Transcription elongation factor B
polypeptide 2
Mitochondrial import inner
membrane translocase subunit
TIM50

56

Gene names

mean fold change
over basal

57

POLR2A

0.72±0.13*

PPP1R8

0.54±0.13*

LMCD1

0.59±0.26

HSD17B8

1.01±0.38

Metaxin-2

MTX2

0.95±0.24

Phosphatase and actin regulator 4

PHACTR4

1.04±0.27

Prolactin-inducible protein

PIP

0.99±0.39

Protein phosphatase 1 regulatory
subunit 11

PPP1R11

1.22±0.17

Protein phosphatase inhibitor 2

PPP1R2;PPP1R2P3

1.04±0.21

60S ribosomal protein L14

RPL14

1.00±0.48

40S ribosomal protein S11

RPS11

1.01±0.25

40S ribosomal protein S25

RPS25

0.79±0.20

Splicing factor 3B subunit 1

SF3B1

1.25±0.54

STAU2

0.91±0.26

STOM

1.28±0.45

SYNCRIP

1.18±0.44

Protein

DNA-directed RNA polymerase II
subunit RPB1
Nuclear inhibitor of protein
phosphatase 1
LIM and cysteine-rich domains
protein 1
Estradiol 17-beta-dehydrogenase
8

Double-stranded RNA-binding
protein Staufen homolog 2
Erythrocyte band 7 integral
membrane protein
Heterogeneous nuclear
ribonucleoprotein Q

57

Protein

Transformer-2 protein homolog
beta
Probable tRNA pseudouridine
synthase 2

Gene names

mean fold change
over basal

58

TRA2B

1.29±0.56

TRUB2

1.08±0.24

Results were shown as mean fold change over basal ± SEM. A 2-fold change indicates
a 2-fold increase, while a 0.5 fold-change indicates a 2-fold decrease. *, P<0.05 vs.
basal. Proteins highlighted in green are PP1c interaction partners showed a significant
increase upon insulin-infusion in humans (>1.3 fold vs. basal, P<0.05). Proteins
highlighted in green are PP1c interaction partners showed an insignificant increase upon
insulin-infusion (>1.3 fold vs. basal, P≥0.05). Proteins highlighted in red are PP1c
interaction partners showed a significant decrease upon insulin-infusion (>1.3 fold
decrease vs. basal or <0.77 fold change over basal, P<0.05). Proteins highlighted in
orange are PP1c interaction partners showed an insignificant decrease upon insulininfusion (>1.3 fold decrease vs. basal or <0.77 fold change over basal, P≥0.05). Proteins
highlighted in yellow are PP1c interaction partners showed less than 1.3 fold change
upon insulin-infusion.
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Ingenuity Canonical Pathways

-log(p-value)

Gene Names

Number of identified PP1c
interaction partners in the study

Table 3 Significantly enriched pathways for the PP1c interaction partners
identified in the study revealed by Ingenuity Pathways Analysis.

EIF2 Signaling

7.68

RPL14,RPL18A,RPS9,PPP1CB,RPL3L,RPS25,PPP1
CA,RPS11

8

Protein Kinase A
Signaling

3.38

PPP1R7,TIMM50,PPP1CB,PPP1R11,PPP1R3A,PPP1
CA

6

Insulin Receptor
Signaling

4.64

PPP1R7,PPP1CB,PPP1R11,PPP1R3A,PPP1CA

5

ERK/MAPK Signaling

3.95

PPP1R7,PPP1CB,PPP1R11,PPP1R3A,PPP1CA

5

Integrin Signaling

3.79

PPP1R12B,ACTB,CAV1,PPP1CB,ACTG1

5

Actin Cytoskeleton
Signaling

3.65

PPP1R12B,ACTB,PPP1CB,ACTG1,F2

5

RhoA Signaling

3.58

PPP1R12B,ACTB,PPP1CB,ACTG1

4
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Protein Phosphatase 1 (PP1), a member of Serine/ Threonine
Phosphatase family, targets its dephosphorylation activity on serine and
threonine residues. As the catalytic subunit of PP1, PP1c can achieve its
substrate specificity only by binding with PP1 regulatory subunits. Previous
researches have shown that PP1c can involve in multiple functional regulation by
associating

with

various

interaction

partners.

Since

serine/

threonine

phosphorylation on the Insulin receptor substrate-1 (IRS1) may direct inactivation
and degradation of IRS1, this phosphorylation activity is believed to be a source
of Insulin Resistance. PP1 is hypothesized to dephosphorylate serine/ threonine
site on IRS1, which may rescue the Insulin resistance.
However, the PP1c interaction partners involve in this process is unclear,
especially in vivo in humans. In the current work, we explored PP1c complexes
in skeletal muscle biopsies from lean healthy participants obtained before insulin

80

81

infusion and after 2 hour insulin infusion, using the proteomic approach
developed in our laboratory. We identified 46 previously unreported endogenous
PP1c interaction partners, which is the largest PP1c interactome in human
skeletal muscle. These novel PP1c interaction partners may serve as new
targets to investigate PP1c complexes in different diseases. Furthermore, we
identified 8 proteins show significantly changes after insulin treatment. These
novel PP1c interactions provide new insights into the molecular mechanism of
insulin action and identify new targets for further PP1c researches in Type 2
Diabetes.
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